Clinical Trial

New clinical data reveals that combining motion preservation with anatomical alignment significantly outperforms traditional spinal fusion outcomes.

As diabetic amputations rise globally, a micro-cap biotech enters Phase 2a trials with a novel topical gel designed to physically destroy drug-resistant superbugs.

Matisse Pharmaceuticals secures €14 million to advance a radically different approach to sepsis, targeting cytotoxic histones to stop organ failure.

Heavy menstrual bleeding drives 600,000 surgeries a year. Hemab Therapeutics aims to replace invasive treatments with a once-a-month injection.

Fennec Pharmaceuticals unveils compelling trial data showing its therapy prevents permanent hearing loss in children undergoing life-saving chemotherapy.

A groundbreaking clinical trial in Lethbridge is utilizing MRI-guided adaptive therapy to condense weeks of prostate cancer radiation into just two treatments.

For 30 years, hair loss treatments have been trapped in a hormonal stalemate. Rubedo Life Sciences is betting its AI-driven senolytic platform can change that.

A breakthrough liquid nitrogen ablation device promises to revolutionize cardiac care, but its maker faces a brutal race against dwindling capital.

IASO208’s FDA clearance marks a critical leap for in vivo CAR-T therapy, promising to strip away manufacturing bottlenecks and reshape global biopharma.

A novel non-viral gene therapy shows early promise in treating Geographic Atrophy, targeting the root cause of iron overload to potentially reverse vision loss.

After decades of setbacks, a new drug from Skyhawk Therapeutics shows patients not just slowing decline, but improving. Is this the breakthrough a desperate community has been waiting for?

Hyperfine has completed a pivotal study for its portable Swoop MRI. Adding contrast could revolutionize point-of-care diagnostics and unlock major market growth.

Imvax has promising data and a clear regulatory path for its glioblastoma therapy. Now it faces the ultimate test: raising millions to fund the final push.

A late-stage biotech is betting on a novel idea: what if we could repair eye damage at a structural level? Stuart Therapeutics' PolyCol™ platform aims to do just that.

Promising trial data for a novel drug targets a stubborn lung cancer mutation, signaling a major strategic advance for BlossomHill Therapeutics and the oncology field.

TOLREMO's successful Phase I trial for TT125-802 validates a novel strategy against NSCLC, offering new hope by targeting cancer's clever escape routes.

Xylo Bio's new drug for depression enters trials, betting it can rewire the brain without the hallucinogenic burden. Is this the future of mental healthcare?

A small biotech assembles top experts to guide a promising, Sanofi-licensed drug through trials, betting it can solve a stubborn cardiovascular challenge.

With impressive Phase 2 data, Revelyx Bio's ready-to-use recombinant toxin YY003 signals a major technological and practical shift for the aesthetics industry.

New research shows a contactless device can predict worsening asthma by listening for coughs, heralding a new era of proactive, data-driven healthcare.